FCMI
RGLS

Foresite Capital Management II’s Regulus Therapeutics RGLS Stock Holding History

Foresite Capital Management II’s Portfolio RGLS Stock Details RGLS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2015
Q4 		– Sell
-2,083
Closed -$1.64M – 26
2015
Q3 		$1.64M Buy
+2,083
New +$2.14M 0.5% 25

Other funds holding RGLS

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Axa
Axa Paris, France $256M AUM 25.01% 1-Year Est. Return
SDIC
South Dakota Investment Council Sioux Falls, South Dakota $5.24B AUM 22.1% 1-Year Est. Return
NI
Numeric Investors Boston, Massachusetts $13.7B AUM 28.88% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return
BIT
BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Foresite Capital Management II's RGLS Position: Q2 2016 in Review

Foresite Capital Management II sold out of Regulus Therapeutics (RGLS) in Q2 2016, closing a stake of 16,991 shares — an estimated $14.1M sold.

Foresite Capital Management II first reported a position in RGLS in Q1 2015 and held it in 5 quarters. The position peaked at $15.3M in Q4 2015. 83 funds tracked by Wall St. Rank hold RGLS as of Q2 2016.

  • Foresite Capital Management II reported no remaining Regulus Therapeutics position as of Q2 2016 after selling out during the quarter.
  • Foresite Capital Management II sold 16,991 Regulus Therapeutics shares in Q2 2016, an estimated $14.1M.
  • Foresite Capital Management II first reported a position in Regulus Therapeutics in Q1 2015 and held it in 5 quarters.
  • Foresite Capital Management II's Regulus Therapeutics position peaked at $15.3M in Q4 2015.
  • 83 funds tracked by Wall St. Rank held Regulus Therapeutics as of Q2 2016.

Based on Foresite Capital Management II's 13F filing for Q2 2016, filed 12 Aug 2016.